Autobio(SH:603658)2023-04-20 16:00Financial Performance - The company's operating revenue for Q1 2023 was CNY 1,036,466,641.85, representing a year-on-year increase of 0.52%[4] - The net profit attributable to shareholders for Q1 2023 was CNY 242,069,910.75, with a year-on-year increase of 0.78%[4] - The net profit attributable to shareholders after deducting non-recurring gains and losses was CNY 235,837,017.97, reflecting a year-on-year increase of 1.61%[4] - The basic and diluted earnings per share for Q1 2023 were both CNY 0.42, a decrease of 2.44% compared to the previous year[6] - Total revenue for Q1 2023 was approximately CNY 1,036.47 million, a slight increase from CNY 1,031.15 million in Q1 2022, representing a growth of 0.33%[16] - Net profit for Q1 2023 was CNY 247.17 million, compared to CNY 246.97 million in Q1 2022, showing a marginal increase of 0.08%[17] - The total comprehensive income for Q1 2023 was CNY 247.05 million, slightly higher than CNY 246.93 million in Q1 2022, indicating a growth of 0.05%[17] Cash Flow - The net cash flow from operating activities for Q1 2023 was CNY 203,712,193.35, showing a significant increase of 11.95% year-on-year[4] - Cash flow from operating activities increased to CNY 1,194.25 million in Q1 2023, compared to CNY 1,155.24 million in Q1 2022, reflecting a growth of 3.38%[19] - The cash flow from operating activities showed a positive trend, indicating improved operational efficiency and revenue generation capabilities[20] - The overall cash position decreased by ¥408,207,092.06 compared to an increase of ¥144,261,270.20 in the same quarter last year[20] Assets and Liabilities - Total assets at the end of Q1 2023 amounted to CNY 10,512,372,555.85, an increase of 0.38% from the end of the previous year[6] - The equity attributable to shareholders at the end of Q1 2023 was CNY 8,024,541,579.52, reflecting a year-on-year increase of 3.11%[6] - The total liabilities of the company were CNY 2.35 billion, down from CNY 2.56 billion, reflecting a decrease of 8.06%[15] - The company's total equity increased to CNY 8.16 billion from CNY 7.91 billion, representing a growth of 3.16%[15] Investments and Expenses - Research and development expenses rose to CNY 152.42 million in Q1 2023, up from CNY 120.79 million in Q1 2022, an increase of 26.19%[16] - Sales expenses decreased to CNY 170.45 million in Q1 2023 from CNY 189.10 million in Q1 2022, a decline of 9.83%[16] - The company reported an increase in investment income to CNY 37.06 million in Q1 2023, compared to CNY 27.80 million in Q1 2022, a growth of 33.38%[16] Cash and Cash Equivalents - The company's cash and cash equivalents were reported at CNY 729.41 million, down from CNY 1.14 billion year-over-year, indicating a decline of 35.87%[13][14] - The cash and cash equivalents at the end of Q1 2023 were ¥728,394,172.47, down from ¥911,656,426.48 at the end of Q1 2022[20] Shareholder Information - The total number of ordinary shareholders at the end of the reporting period was not specified, but the largest shareholder held 55.24% of the shares[9] Non-Recurring Items - The company reported non-recurring gains of CNY 6,232,892.78 for the period, after accounting for tax and minority interests[8] Other Information - The company has not disclosed any new product launches or technological advancements in this report[12] - The company has not adopted new accounting standards or interpretations for the year 2023[21]